For decades, medicine has treated the symptoms of diseases. But in 2026, a quiet shift is taking place in laboratories and hospitals worldwide: more and more treatments are focusing on correcting the root cause of disorders — the DNA itself. Biotechnology, driven by decades of research and an unprecedented acceleration after the pandemic, has entered a new phase of maturity.
More than 30 gene therapies have been approved by regulatory agencies worldwide since 2020, and at least a dozen more are awaiting approval in 2026.
From lab to patient: the gene therapy revolution
Gene therapies, which involve introducing a functional copy of a gene into a patient's cells, are no longer a future promise. Diseases such as spinal muscular atrophy, hemophilia B, and certain types of inherited blindness now have treatment options that directly target the causative mutation. The main challenge remains cost: some treatments exceed one million dollars per patient, raising urgent questions about access and the sustainability of healthcare systems.
But the field is advancing rapidly. New gene-editing techniques, such as CRISPR and its improved versions, now allow precise changes to the genome without needing to insert entire genes. In 2026, the first clinical trials with in vivo gene editing — inside the patient's body — are showing promising results for liver diseases and blood disorders.
What is gene editing?
Gene editing allows precise modification of a cell's DNA. The best-known tool is CRISPR-Cas9, which acts like molecular scissors capable of cutting and replacing defective segments of the genome. In 2026, new generations of this technology offer greater precision and fewer side effects.
Cancer, the new battlefield
One of the fields where biotechnology is making the most tangible difference is oncology. CAR-T therapies, which modify a patient's immune cells to attack tumors, have become a standard option for certain blood cancers. In 2026, researchers are testing more potent and safer versions capable of fighting solid tumors, such as lung or pancreatic cancer, which have resisted this approach so far.
Moreover, the combination of artificial intelligence with molecular biology is accelerating drug discovery. Algorithms trained on millions of genomic data points can predict which molecules will be most effective against a defective protein, cutting years off pre-clinical research. However, experts warn that AI does not replace lab experimentation but complements it.
The challenge of global access
While developed countries begin integrating these therapies into their healthcare systems, most of the world's population still lacks access. Production costs, the need for specialized hospital infrastructure, and a shortage of medical training in genetics are enormous barriers. International organizations and governments in emerging countries are exploring voluntary licensing models and local production to reduce prices, a path already taken with HIV drugs.
Biotechnology is not just a story of advanced laboratories. It is also a story of political decisions, investment in basic science, and global cooperation. In 2026, the true success of this revolution will be measured not only by the number of approved therapies, but by how many people can benefit from them, regardless of where they were born.
What does this mean for the world?
Genetic medicine represents a paradigm shift: moving from treating diseases to preventing or curing them at their source. In the coming years, the challenge will be to ensure that these advances do not widen the gap between rich and poor countries, but become a common good. Science has taken the step; now it is up to society and governments to decide how to share its fruits.